Applied DNA Sciences (APDN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $5.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.03%. A quarter ago, it was expected that this DNA-based security technology company would post a loss of $0.64 per share when it actually produced earnings of $0.47, delivering a surprise of 173.44%.Over the last fo ...

Table of Contents | --- | |-------| | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | |--------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------| | 50 Health Sciences Drive, Stony Brook, New York | 11790 | (631) 240-8800 | | (Address of principal executive offices) | (Zip Code) Securities registered pursuant to Section 12(b) of t ...

Exhibit 99.1 Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines - Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Buildout of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET - STONY BROOK, N.Y. – December 17, 2024 - Applied D ...

The World Health Organization (WHO) is a branch of the United Nations dedicated to health. Founded in 1948, the WHO’s primary roles include supervising and coordinating health programs. The WHO also monitors health trends, establishes guidelines and suggestions, and supports countries that need it. Moreover, the WHO leads efforts to control diseases, improve healthcare systems, and tackle health emergencies and pandemics. WHO Declares Monkeypox State of EmergencyHealth officials at the world’s most-followed ...

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q3 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Corporate Participants Sanjay Hurry - Head of IR Beth Jantzen - Chief Financial Officer Jim Hayward - Chairman, President and Chief Executive Officer Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Operator Good day, and welcome to the Applied DNA Fiscal Third Quarter 2024 Investor Conference Call. All participants will be listen-only mode. [Operator Instructi ...

Applied DNA Sciences (APDN) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.64 per share. This compares to loss of $4.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 173.44%. A quarter ago, it was expected that this DNA-based security technology company would post a loss of $4.60 per share when it actually produced a loss of $5.31, delivering a surprise of -15.43%.Ov ...

Exhibit 99.1 Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, N.Y. – August 8, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its third fiscal quarter ended June 30, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. Third Quarter Operational Highlig ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Investors might want to bet on Applied DNA Sciences (APDN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Applied DNA Sciences (APDN) came out with a quarterly loss of $5.31 per share versus the Zacks Consensus Estimate of a loss of $4.60. This compares to loss of $4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -15.43%. A quarter ago, it was expected that this DNA-based security technology company would post a loss of $6.20 per share when it actually produced a loss of $1.80, delivering a surprise of 70.97%.Over the last four q ...